Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234963 | 0.81 | GAA (0.40) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL853230 | 0.80 | GAA (0.42) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL855206 | 0.79 | GAA (0.46) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL853994 | 0.79 | GAA (0.46) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL853966 | 0.69 | GAA (0.36) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL31327082 | 0.68 | GAA (0.38) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL6968729 | 0.62 | GAA (0.47) | TDP1GAAALDH1A1MAPTMEN1 | |
| SCHEMBL9577660 | 0.62 | MEN1 (0.39) | ALDH1A1MEN1KMT2ADGAT1TRPV6 | |
| SCHEMBL5615220 | 0.61 | EPHX1 (0.42) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL22797 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234020-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. | 2005-10-20 | — | — | US | claimed |
| EP-1556059-A1 | THROMBOPOIETIN MIMETICS | Smithkline Beecham (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2003103686-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | claimed |
| US-7414040-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414040-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414040-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-20050234020-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1556059-A1 | THROMBOPOIETIN MIMETICS | Smithkline Beecham (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103686-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234020-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | TDP1 2922/4885GAA 2853/4885ALDH1A1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.